Advertisement
Canada markets close in 2 hours 59 minutes
  • S&P/TSX

    21,841.62
    -32.10 (-0.15%)
     
  • S&P 500

    5,033.35
    -38.28 (-0.75%)
     
  • DOW

    38,007.20
    -453.72 (-1.18%)
     
  • CAD/USD

    0.7310
    +0.0013 (+0.17%)
     
  • CRUDE OIL

    82.61
    -0.20 (-0.24%)
     
  • Bitcoin CAD

    88,121.61
    -430.98 (-0.49%)
     
  • CMC Crypto 200

    1,387.31
    +4.74 (+0.34%)
     
  • GOLD FUTURES

    2,342.80
    +4.40 (+0.19%)
     
  • RUSSELL 2000

    1,971.72
    -23.70 (-1.19%)
     
  • 10-Yr Bond

    4.6960
    +0.0440 (+0.95%)
     
  • NASDAQ

    15,545.59
    -167.16 (-1.06%)
     
  • VOLATILITY

    16.47
    +0.50 (+3.13%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6808
    -0.0011 (-0.16%)
     

DEADLINE ALERT for ACRX and RLX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Aug. 04, 2021 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com.

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
Class Period: March 17, 2020 – February 12, 2021
Lead Plaintiff Deadline: August 9, 2021

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) AcelRx had deficient disclosure controls and procedures with respect to its marketing of DSUVIA; (2) as a result, AcelRx had been making false or misleading claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays; (3) the foregoing conduct subjected the Company to increased regulatory scrutiny and enforcement; and (4) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

ADVERTISEMENT

RLX Technology Inc. (NYSE: RLX)
Class Period: January 2021 IPO
Lead Plaintiff Deadline: August 9, 2021

The complaint alleges that Defendants overstated certain financial metrics and failed to disclose that these metrics were not indicative of future financial performance since regulators in China were already working on a national standard for e-cigarettes that would regulate them either under the same rules or in the same manner as ordinary cigarettes.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com